Skip to main content

MAXCYTE INC

For the period ended Mar 31, 2024. Filed May 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

MXCT$1.30+3.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

​​​​​​​​
​ · ​ · ​ · Three Months Ended March 31,
​ · ​ · ​ · 2024 · ​ · 2023
Revenue​​$11,342​$8,576
Cost of goods sold​​1,403​1,000
Gross profit​​9,939​7,576
​​​​​​​​
Operating expenses:​​​
Research and development​​6,678​6,047
Sales and marketing​​7,365​6,296
General and administrative​​7,103​7,499
Depreciation and amortization​​​1,068​​912
Total operating expenses​​22,214​20,754
Operating loss​​(12,275)​(13,178)
​​​​​​​​
Other income:​​​
Interest income​​2,749​2,296
Total other income​​2,749​2,296
Loss before income taxes​​​(9,526)​​(10,882)
Provision for income taxes​​​—​​—
Net loss​​$(9,526)​$(10,882)
Basic and diluted net loss per share​​$(0.09)​$(0.11)
Weighted average shares outstanding, basic and diluted​​104,089,758​102,846,036
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.